Tim Ahfeldt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tim Ahfeldt has a total of 284 co-authors. Here are the top co-authors by number of shared publications:
- Joel Blanchard
Nash Family Department of Neuroscience & Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York City, NY, USA
6 shared publications - Chad A. Cowan
Department of Stem Cell and Regenerative Biology, Harvard University, Cambridge, Massachusetts 02138, USA
4 shared publications Elena Coccia
Nash Family Department of Neuroscience, Mount Sinai, New York, NY 10029, USA
4 shared publicationsFrank H. Lau
Department of Surgery, Massachusetts General Hospital, Boston, MA 02114, USA
4 shared publications- Lee L. Rubin
Department of Stem Cell and Regenerative Biology, Harvard University
4 shared publications Lily Sarrafha
Icahn School of Medicine, Mount Sinai, New York, NY, USA
4 shared publications
Latest Publications
- Open Access
- 22 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9394
A New Selection Strategy to Enrich Dopaminergic Neurons Facilitates Comparisons Between Patient iPSC-Derived Lines
Comparative studies of dopaminergic (DA) neurons differentiated from induced pluripotent stem cells (iPSCs) derived from patients discordant for parkinsonism, especially siblings, provide a valuable model to explore factors underlying Parkinson disease (PD) pathogenesis. However, such studies are complicated by the inherent heterogeneity in differentiation efficiency among iPSC lines derived from different individuals. To address this technical challenge, we devised a selection strategy to enrich DA neurons expressing tyrosine hydroxylase (TH). A neomycin resistance gene (neo) was inserted at the C-terminus of the TH gene, placing its expression under the endogenous promoter. Using iPSC-derived neurons from a healthy individual (HT711), we achieved selective enrichment of TH+ neurons through geneticin selection without compromising differentiation capacity, as demonstrated by Western blots, immunocytochemistry and flow cytometry. We then applied the method to iPSCs derived from two siblings of HT711, one with Gaucher disease (GD) alone and one with both PD and GD. Quantification of multiple DA neuron markers through whole-cell proteomics confirmed their comparable enrichment in the three lines, demonstrating that the new method can be applied to iPSC lines from different individuals to standardize DA neuron cultures. While we focus on methodological developments here, a companion analysis of the same whole-cell proteomics dataset, examining molecular features potentially associated with disease statuses, has been reported separately.
- 22 October 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (21) , 9394
Open AccessA New Selection Strategy to Enrich Dopaminergic Neurons Facilitates Comparisons Between Patient iPSC-Derived Lines
Comparative studies of dopaminergic (DA) neurons differentiated from induced pluripotent stem cells (iPSCs) derived from patients discordant for parkinsonism, especially siblings, provide a valuable model to explore factors underlying Parkinson disease (PD) pathogenesis. However, such studies are complicated by the inherent heterogeneity in differentiation efficiency among iPSC lines derived from different individuals. To address this technical challenge, we devised a selection strategy to enrich DA neurons expressing tyrosine hydroxylase (TH). A neomycin resistance gene (neo) was inserted at the C-terminus of the TH gene, placing its expression under the endogenous promoter. Using iPSC-derived neurons from a healthy individual (HT711), we achieved selective enrichment of TH+ neurons through geneticin selection without compromising differentiation capacity, as demonstrated by Western blots, immunocytochemistry and flow cytometry. We then applied the method to iPSCs derived from two siblings of HT711, one with Gaucher disease (GD) alone and one with both PD and GD. Quantification of multiple DA neuron markers through whole-cell proteomics confirmed their comparable enrichment in the three lines, demonstrating that the new method can be applied to iPSC lines from different individuals to standardize DA neuron cultures. While we focus on methodological developments here, a companion analysis of the same whole-cell proteomics dataset, examining molecular features potentially associated with disease statuses, has been reported separately.
- Top Cited PapersOpen Access
- 7 August 2026
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 25 (11) , 855-876
Artificial intelligence in drug discovery — what it is, where we stand and the path forward
- 7 August 2026
- Published by Springer Nature in Nature Reviews Drug Discovery
- Vol. 25 (11) , 855-876
Top Cited PapersOpen AccessArtificial intelligence in drug discovery — what it is, where we stand and the path forward
- Open Access
ATP13A2 Loss of Function-Driven Polyamine Dysregulation Induces SAM Depletion and Epigenetic Astrocyte Toxicity
Aging is the strongest risk factor for neurodegeneration, yet how the human brain ages remains poorly understood. Loss-of-function (LOF) variants in ATP13A2 cause severe juvenile-onset Parkinson’s disease, providing a window into the mechanisms that accelerate age-related neurodegeneration. ATP13A2-LOF causes lysosomal polyamine sequestration, but how this promotes pathogenesis remains unclear. We discovered that ATP13A2-LOF depletes cytosolic polyamines in astrocytes, triggering compensatory upregulation of de novo polyamine biosynthesis, which diverts S-adenosyl methionine (SAM) from DNA and histone methylation, leading to increased chromatin accessibility and epigenetic reprogramming of astrocytes into a neuroinflammatory state that releases neurotoxic cytokines that promote dopaminergic neuron death. In ATP13A2 knockout mice and human models, we find that genetic and pharmacological inhibition of SAM utilization in polyamine biosynthesis prevents astrocytic epigenetic reprogramming and promotes dopaminergic neuron survival. These findings reveal a direct link between polyamine metabolism, epigenetic dysfunction, and neurotoxic inflammation, uncovering new therapeutic opportunities in Parkinson’s disease.
Open AccessATP13A2 Loss of Function-Driven Polyamine Dysregulation Induces SAM Depletion and Epigenetic Astrocyte Toxicity
Aging is the strongest risk factor for neurodegeneration, yet how the human brain ages remains poorly understood. Loss-of-function (LOF) variants in ATP13A2 cause severe juvenile-onset Parkinson’s disease, providing a window into the mechanisms that accelerate age-related neurodegeneration. ATP13A2-LOF causes lysosomal polyamine sequestration, but how this promotes pathogenesis remains unclear. We discovered that ATP13A2-LOF depletes cytosolic polyamines in astrocytes, triggering compensatory upregulation of de novo polyamine biosynthesis, which diverts S-adenosyl methionine (SAM) from DNA and histone methylation, leading to increased chromatin accessibility and epigenetic reprogramming of astrocytes into a neuroinflammatory state that releases neurotoxic cytokines that promote dopaminergic neuron death. In ATP13A2 knockout mice and human models, we find that genetic and pharmacological inhibition of SAM utilization in polyamine biosynthesis prevents astrocytic epigenetic reprogramming and promotes dopaminergic neuron survival. These findings reveal a direct link between polyamine metabolism, epigenetic dysfunction, and neurotoxic inflammation, uncovering new therapeutic opportunities in Parkinson’s disease.
- Open Access
Genetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven by PRKN knockout
Summary: Cellular processes including lysosomal and mitochondrial dysfunction are implicated in the development of many diseases. Quantitative visualization of mitochondria and lysosomes is crucial to understand how these organelles are dysregulated during disease. To address a gap in live-imaging tools, we developed GEM-SCOPe (Genetically Encoded and Modular SubCellular Organelle Probes), a modular toolbox of fluorescent markers designed to inform on localization, distribution, turnover, and oxidative stress of specific organelles. We expressed GEM-SCOPe in differentiated astrocytes and neurons from a human pluripotent stem cell PRKN- knockout model of Parkinson’s disease and identified disease-associated changes in proliferation, lysosomal distribution, mitochondrial transport and turnover, and reactive oxygen species. We demonstrate GEM-SCOPe is a powerful panel that provide critical insight into the subcellular mechanisms underlying Parkinson’s disease in human cells. GEM-SCOPe can be expanded upon and applied to a diversity of cellular models to glean an understanding of the mechanisms that promote disease onset and progression.
Open AccessGenetically Encoded and Modular SubCellular Organelle Probes (GEM-SCOPe) reveal lysosomal and mitochondrial dysfunction driven by PRKN knockout
Summary: Cellular processes including lysosomal and mitochondrial dysfunction are implicated in the development of many diseases. Quantitative visualization of mitochondria and lysosomes is crucial to understand how these organelles are dysregulated during disease. To address a gap in live-imaging tools, we developed GEM-SCOPe (Genetically Encoded and Modular SubCellular Organelle Probes), a modular toolbox of fluorescent markers designed to inform on localization, distribution, turnover, and oxidative stress of specific organelles. We expressed GEM-SCOPe in differentiated astrocytes and neurons from a human pluripotent stem cell PRKN- knockout model of Parkinson’s disease and identified disease-associated changes in proliferation, lysosomal distribution, mitochondrial transport and turnover, and reactive oxygen species. We demonstrate GEM-SCOPe is a powerful panel that provide critical insight into the subcellular mechanisms underlying Parkinson’s disease in human cells. GEM-SCOPe can be expanded upon and applied to a diversity of cellular models to glean an understanding of the mechanisms that promote disease onset and progression.
- Top Cited PapersOpen Access
- 12 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (2) , eadi8287
Molecular profiling of human substantia nigra identifies diverse neuron types associated with vulnerability in Parkinson’s disease
Parkinson’s disease (PD) is characterized pathologically by the loss of dopaminergic (DA) neurons in the substantia nigra (SN). Whether cell types beyond DA neurons in the SN show vulnerability in PD remains unclear. Through transcriptomic profiling of 315,867 high-quality single nuclei in the SN from individuals with and without PD, we identified cell clusters representing various neuron types, glia, endothelial cells, pericytes, fibroblasts, and T cells and investigated cell type–dependent alterations in gene expression in PD. Notably, a unique neuron cluster marked by the expression of RIT2 , a PD risk gene, also displayed vulnerability in PD. We validated RIT2 -enriched neurons in midbrain organoids and the mouse SN. Our results demonstrated distinct transcriptomic signatures of the RIT2 -enriched neurons in the human SN and implicated reduced RIT2 expression in the pathogenesis of PD. Our study sheds light on the diversity of cell types, including DA neurons, in the SN and the complexity of molecular and cellular changes associated with PD pathogenesis.
- 12 January 2024
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 10 (2) , eadi8287
Top Cited PapersOpen AccessMolecular profiling of human substantia nigra identifies diverse neuron types associated with vulnerability in Parkinson’s disease
Parkinson’s disease (PD) is characterized pathologically by the loss of dopaminergic (DA) neurons in the substantia nigra (SN). Whether cell types beyond DA neurons in the SN show vulnerability in PD remains unclear. Through transcriptomic profiling of 315,867 high-quality single nuclei in the SN from individuals with and without PD, we identified cell clusters representing various neuron types, glia, endothelial cells, pericytes, fibroblasts, and T cells and investigated cell type–dependent alterations in gene expression in PD. Notably, a unique neuron cluster marked by the expression of RIT2 , a PD risk gene, also displayed vulnerability in PD. We validated RIT2 -enriched neurons in midbrain organoids and the mouse SN. Our results demonstrated distinct transcriptomic signatures of the RIT2 -enriched neurons in the human SN and implicated reduced RIT2 expression in the pathogenesis of PD. Our study sheds light on the diversity of cell types, including DA neurons, in the SN and the complexity of molecular and cellular changes associated with PD pathogenesis.
- Open Access
Novel human pluripotent stem cell-derived hypothalamus organoids demonstrate cellular diversity
- Open Access
Disruption of lysosomal proteolysis in astrocytes facilitates midbrain proteostasis failure in an early-onset PD model
SUMMARY: Accumulation of advanced glycation end products (AGEs) on biopolymers accompany cellular aging and drives poorly understood disease processes. Here, we studied how AGEs contribute to development of early on-set Parkinson’s Disease (PD) caused by loss-of-function of DJ1, a protein deglycase. In induced pluripotent stem cell (iPSC)-derived midbrain organoid models deficient for DJ1 activity, we find that lysosomal proteolysis is impaired, causing AGEs to accumulate, α-synuclein (α-syn) phosphorylation to increase, and proteins to aggregate. These processes are at least partly driven by astrocytes, as DJ1 loss reduces their capacity to provide metabolic support and triggers acquisition of a pro-inflammatory phenotype. Consistently, in co-cultures, we find that DJ1-expressing astrocytes are able to reverse the proteolysis deficits of DJ1 knockout midbrain neurons. In conclusion, astrocytes’ capacity to clear toxic damaged proteins is critical to preserve neuronal function and their dysfunction contributes to the neurodegeneration observed in PD.
Open AccessDisruption of lysosomal proteolysis in astrocytes facilitates midbrain proteostasis failure in an early-onset PD model
SUMMARY: Accumulation of advanced glycation end products (AGEs) on biopolymers accompany cellular aging and drives poorly understood disease processes. Here, we studied how AGEs contribute to development of early on-set Parkinson’s Disease (PD) caused by loss-of-function of DJ1, a protein deglycase. In induced pluripotent stem cell (iPSC)-derived midbrain organoid models deficient for DJ1 activity, we find that lysosomal proteolysis is impaired, causing AGEs to accumulate, α-synuclein (α-syn) phosphorylation to increase, and proteins to aggregate. These processes are at least partly driven by astrocytes, as DJ1 loss reduces their capacity to provide metabolic support and triggers acquisition of a pro-inflammatory phenotype. Consistently, in co-cultures, we find that DJ1-expressing astrocytes are able to reverse the proteolysis deficits of DJ1 knockout midbrain neurons. In conclusion, astrocytes’ capacity to clear toxic damaged proteins is critical to preserve neuronal function and their dysfunction contributes to the neurodegeneration observed in PD.
- Open Access
- 25 October 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (24) , 5082-5098.e11
Temporal proteomics during neurogenesis reveals large-scale proteome and organelle remodeling via selective autophagy
- 25 October 2021
- Published by Elsevier in Molecular Cell
- Vol. 81 (24) , 5082-5098.e11
Open AccessTemporal proteomics during neurogenesis reveals large-scale proteome and organelle remodeling via selective autophagy
- Open Access
- 1 June 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (2) , 100463
High-throughput generation of midbrain dopaminergic neuron organoids from reporter human pluripotent stem cells
- 1 June 2021
- Published by Elsevier in STAR Protocols
- Vol. 2 (2) , 100463
Open AccessHigh-throughput generation of midbrain dopaminergic neuron organoids from reporter human pluripotent stem cells